Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Borbeau Joins BD; Maag New CEO of XDx; NanoString Appoints James Johnson as CFO

Premium

BD Diagnostics said that Paul Borbeau has joined the company as director of North American scientific affairs for diagnostic systems.

Borbeau most recently served as director of microbiology for Geisinger Medical Laboratories. He is also currently the associate editor of the Journal of Clinical Microbiology. Borbeau received a PhD in microbiology from Temple University School of Medicine and completed post-graduate training in clinical microbiology at Hartford Hospital in Conn.


XDx has appointed Peter Maag as president and CEO.

Prior to joining XDx, Maag was president of Novartis Diagnostics, where he accelerated growth in the company's blood screening business, which screens 80 percent of the US and 30 percent of the global blood supply. Prior to that, Maag served as country president for Novartis Pharma in Germany. He has also held various senior roles at Novartis, including country president in Korea, head of infectious disease in Switzerland, and head of strategy for the pharma division. Prior to joining Novartis, Maag worked at McKinsey & Company in New Jersey and Germany. He holds a PhD from the University of Berlin in Germany.


NanoString Technologies said this week that it has appointed James Johnson as chief financial officer.

Johnson will assume this role from Wayne Burns, who will remain with the company as senior vice president of operations and finance.

Johnson joins NanoString from Relypsa, where was CFO. Prior to that he spent nearly ten years with ZymoGenetics, where was most recently executive vice president, CFO, treasurer, and secretary. He has also held financial positions at Targeted Genetics and Immunex.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.